PharmaLectures.com

Courses › Country and business playbooks › Selling into Europe as a biologics and biosimilars maker from the United States

Selling into Europe as a biologics and biosimilars maker from the United States

Your biologic reaches European patients without a dossier query or a held shipment.

  • 12 audio modulesthree lengths each
  • 2 h to 10 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • United States, Biologics and biosimilarswho it is written for

Why this training matters

The European Medicines Agency queries a manufacturing site entry in your Module 3, and the review clock stops. Your team rewrites the dossier while the launch date slips and finished product waits in cold storage. Nobody in the United States office knew which section the reviewer would check first.

What changes after this course

Your regulatory, safety, supply chain and market access staff file, ship and price to the same European rules. Each learner who passes the recorded questionnaire gets an individual certificate. You hold the training record showing who finished which module.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

The Marketing Authorization Application goes out right the first time. Your regulatory team lays out Module 3 of the Common Technical Document the way European Medicines Agency reviewers read it. Manufacturing site entries match across sections, and comparability data follows the similar biological medicinal products guideline. The reviewer finds the answer before writing the query.

Shipments stop being a guess at the border. Your supply chain managers apply Good Distribution Practice at every handover, put the Harmonized System code where customs look for it, and check labels and storage records before the truck leaves. When a forwarder calls with a question, the answer is already in the file.

Pricing talks start from the local payer's question, not from one European price. Your market access leads know what national health technology assessment bodies weigh, which clinical data to bring, and when to approach payers before launch. They also see where parallel trade and reimbursement rules cut across the plan.

Safety work runs on dates you can defend. Your pharmacovigilance team knows the Good Pharmacovigilance Practices timelines, files in EudraVigilance without second-guessing a deadline, and keeps a Pharmacovigilance System Master File that fits Implementing Regulation (EU) No 520/2012. The qualified person is named, based in the European Union, and reachable.

Who needs this training

  • Regulatory Affairs Manager, Biologics

    The week before submission, you check Module 3 against what the European Medicines Agency expects and know the site entries and comparability data will hold up when the reviewer opens them.

  • Market Access Lead, European Expansion

    In the pricing meeting for Germany or France, you bring the clinical evidence that the local assessment body asks for instead of one European price slide.

  • Global Supply Chain Director

    When a biologic batch sits at a border, you know which Good Distribution Practice records and Harmonized System code support the customs answer, and you ask the forwarder for them.

  • Pharmacovigilance Specialist

    When the inspector asks for your Pharmacovigilance System Master File, you hand over one that matches your EudraVigilance reporting history and names a qualified person in the European Union.

  • Quality Assurance Manager, Manufacturing Site

    On the morning an inspector arrives without notice, you know which records they ask for, and your team knows who answers.

Roles: Owner, CEO and board, Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person

Businesses: Biologics and biosimilars

Countries: United States

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Lay out Module 3 of the Common Technical Document with consistent manufacturing site entries that a European Medicines Agency reviewer can check quickly.
  2. Decide whether your biologic must use the centralised procedure under Regulation (EC) No 726/2004 or may choose it.
  3. Build a Pharmacovigilance System Master File that fits Implementing Regulation (EU) No 520/2012 and name a qualified person based in the European Union.
  4. Choose the evidence a national health technology assessment body expects for your biosimilar before you meet its payers.
  5. Put the right Harmonized System code and Good Distribution Practice record on every cross-border biologic shipment.
  6. Classify a manufacturing change and file the right post-launch variation before the changed product ships.

What the company gets

  • Your Marketing Authorization Application reaches the European Medicines Agency with Module 3 checked section by section.
  • Your Pharmacovigilance System Master File is ready when an inspector asks for it, with a named qualified person in the European Union.
  • Logistics teams answer a customs or Good Distribution Practice question from the file, so a shipment keeps moving.
  • Your market access leads arrive at each national payer with evidence matched to that payer's assessment, not a generic European deck.
  • Every learner holds a certificate, and your training record shows who completed each module when an auditor asks.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 12 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing2 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard5 h25 min a module, for regulatory, quality and business-development staff
Expanded10 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Owner, CEO and boardBriefing2 h
Business development and export salesBriefing2 h
Regulatory affairsStandard5 h
Quality assurance and Qualified PersonStandard5 h

Course outline: 12 modules

12 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Map how your biologic reaches patients across European member states

    • Why a European approval opens the market yet does not get your biologic a single prescription.
    • How to spot which member states price and reimburse differently before you set your launch order.
    • The moment to bring in national stakeholders so your launch date survives its first contact with payers.
  2. 2Apply Regulation (EC) No 726/2004 to your centralised procedure

    • How to tell whether your biologic must use the centralised procedure or may choose it.
    • What Directive 2001/83/EC still asks of your biological product when you file centrally.
    • Who decides what between the Commission, the agency and national regulators, so you ask the right desk.
  3. 3Format Module 3 of your Common Technical Document so reviewers accept it

    • How to lay out Module 3 Quality so the reviewer finds each answer without writing back.
    • The manufacturing site entry in Module 3 that draws a query when it is missing or inconsistent.
    • What to do when the drug substance and the drug product are made at different sites.
  4. 4Prove biosimilarity with the European comparability guidelines

    • Why European reviewers look for similarity across the whole data package, not an identical molecule.
    • How to apply guideline EMA/CHMP/BMWP/403543/2010 to your monoclonal antibody comparability data.
    • What to do when your comparability data shows a minor structural difference you did not plan for.
  5. 5Set up Good Pharmacovigilance Practices and appoint the right officers

    • How Good Pharmacovigilance Practices set your adverse event reporting clock, and where to start it.
    • Why your qualified person for pharmacovigilance must live and work in the European Union.
    • How to catch a late or incomplete EudraVigilance submission before an inspector does.
  6. 6Align your dossier with national health technology assessments

    • Why a centralised approval leaves each member state free to set its own price.
    • How national health technology assessment bodies weigh clinical benefit against cost for your biosimilar.
    • The clinical evidence an assessment body asks for before it recommends that anyone pays.
  7. 7Build a market access strategy that wins over local European payers

    • How to shape a value story that holds up in markets with different prices and rules.
    • When to approach local payers before launch, and when it is still too early.
    • What happens to uptake when a local reimbursement rule is missed, and how to avoid it.
  8. 8Keep biologics compliant in transit with Good Distribution Practice

    • How Good Distribution Practice protects the cold chain at every border handover.
    • Where Harmonized System codes belong on your shipping paperwork so customs questions meet a ready answer.
    • Why a label or storage deviation in transit can put a whole batch on hold.
  9. 9Protect patient data under the General Data Protection Regulation

    • How parallel trade across European borders can undercut the price you set in a higher-priced market.
    • What the General Data Protection Regulation requires when your clinical work touches patient data.
    • How to protect your biologic's patents and regulatory data protection before a copy reaches market.
  10. 10Submit post-launch variations without triggering a recall

    • How to classify a manufacturing change and file the right variation under Regulation (EC) No 1234/2008.
    • The risk management plan and pharmacovigilance duties that stay with every approved biosimilar.
    • Why a manufacturing site change must wait for approval under Regulation (EC) No 1234/2008.
  11. 11Pass European Good Manufacturing Practice site inspections

    • What inspectors ask to see when they walk through your Good Manufacturing Practice site.
    • How to get your quality management system ready for an inspection that arrives without notice.
    • The audit findings that can put a hard-won marketing authorization under review.
  12. 12Adapt your filings to Advanced Therapy Medicinal Products guidelines

    • How Regulation (EC) No 1394/2007 separates Advanced Therapy Medicinal Products from your biologic filing.
    • How the European Health Data Space and the Health Technology Assessment Regulation may change your market access.
    • When digital health trends matter to your filing, and when they can wait.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

12 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 2 h in the briefing length and 10 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for United States, Biologics and biosimilars. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 108 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team